Biomarin Pharmaceutical Inc (BMRN)vsVertex Pharmaceuticals Inc (VRTX)
BMRN
Biomarin Pharmaceutical Inc
$56.77
+0.53%
HEALTHCARE · Cap: $10.81B
VRTX
Vertex Pharmaceuticals Inc
$446.83
+1.24%
HEALTHCARE · Cap: $107.89B
Smart Verdict
WallStSmart Research — data-driven comparison
Vertex Pharmaceuticals Inc generates 277% more annual revenue ($12.22B vs $3.24B). VRTX leads profitability with a 35.5% profit margin vs 8.3%. BMRN appears more attractively valued with a PEG of 0.69. VRTX earns a higher WallStSmart Score of 68/100 (B-).
BMRN
Buy55
out of 100
Grade: C-
VRTX
Strong Buy68
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+65.7%
Fair Value
$175.57
Current Price
$56.77
$118.80 discount
Margin of Safety
+53.1%
Fair Value
$952.53
Current Price
$446.83
$505.70 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Safe zone — low bankruptcy risk
Conservative balance sheet, low leverage
Growing faster than its price suggests
Reasonable price relative to book value
Keeps 36 of every $100 in revenue as profit
Strong operational efficiency at 38.1%
Earnings expanding 61.4% YoY
Safe zone — low bankruptcy risk
Large-cap with strong market position
Every $100 of equity generates 22 in profit
Areas to Watch
2.8% revenue growth
ROE of 4.3% — below average capital efficiency
Weak financial health signals
Premium valuation, high expectations priced in
Expensive relative to growth rate
Moderate valuation
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : BMRN
The strongest argument for BMRN centers on Altman Z-Score, Debt/Equity, PEG Ratio. PEG of 0.69 suggests the stock is reasonably priced for its growth.
Bull Case : VRTX
The strongest argument for VRTX centers on Profit Margin, Operating Margin, EPS Growth. Profitability is solid with margins at 35.5% and operating margin at 38.1%.
Bear Case : BMRN
The primary concerns for BMRN are Revenue Growth, Return on Equity, Piotroski F-Score. A P/E of 40.3x leaves little room for execution misses.
Bear Case : VRTX
The primary concerns for VRTX are PEG Ratio, P/E Ratio, Piotroski F-Score.
Key Dynamics to Monitor
BMRN profiles as a value stock while VRTX is a mature play — different risk/reward profiles.
VRTX carries more volatility with a beta of 0.30 — expect wider price swings.
VRTX is growing revenue faster at 7.8% — sustainability is the question.
VRTX generates stronger free cash flow (1.3B), providing more financial flexibility.
Bottom Line
VRTX scores higher overall (68/100 vs 55/100), backed by strong 35.5% margins. BMRN offers better value entry with a 65.7% margin of safety. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Biomarin Pharmaceutical Inc
HEALTHCARE · BIOTECHNOLOGY · USA
BioMarin Pharmaceutical Inc. develops and markets therapies for people with rare diseases and serious and life-threatening medical conditions. The company is headquartered in San Rafael, California.
Vertex Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Vertex Pharmaceuticals, Inc. is an American biopharmaceutical company based in Boston, Massachusetts.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?